Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.
Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers
Google Scholar citation report
Citations : 2820
Epidemiology: Open Access received 2820 citations as per Google Scholar report
Epidemiology: Open Access peer review process verified at publons
Indexed In
- Index Copernicus
- Google Scholar
- Sherpa Romeo
- Genamics JournalSeek
- SafetyLit
- Access to Global Online Research in Agriculture (AGORA)
- Centre for Agriculture and Biosciences International (CABI)
- RefSeek
- Hamdard University
- EBSCO A-Z
- OCLC- WorldCat
- CABI full text
- Cab direct
- Publons
- Geneva Foundation for Medical Education and Research
- Euro Pub
- ICMJE
Useful Links
Recommended Journals
Related Subjects
Share This Page
In Association with
Efficacy of diethylcarbamazine and thiabendazole in albendazole and mebendazole resistant toxocariasis
3rd International Conference on Epidemiology & Public Health
Wojciech Ozimek and Montserrat Gras Graupera
Posters-Accepted Abstracts: Epidemiology (Sunnyvale)
Abstract
Human infections with Toxocaracanis and cati are clinically important subjects and a frequent cause of misdiagnosis or
delayed diagnosis. Despite the recognition of toxocariasis as an important clinical illness there have been few reviews
of therapy for these infections and no definitive treatment protocols have been published, especially in albendazole and
mebendazole resistant cases. Only a handful of agents have been used in therapy, and the agents which are available may vary
in significantly in efficacy and have adverse effects or be contraindicated in certain clinical situations. When evaluating the
clinical efficacy of agents used against toxocara infections, it is difficult to compare studies. They vary as to entry methodology
(whether randomization was done and if treatment was blinded or open), population studied (children, adults), syndromes
treated: visceral larva migrans (VLM), covert toxocariasis- milder version of VLM and ocular larva migrans (OLM), measures
(clinical efficacy and/or blood results negativity), and duration of follow-up. Nevertheless, conclusions may be drawn from
the studies when viewed as a whole, and statements can be made about the relative efficacy of the agents. In this paper we
present our own experiences and initial results about the efficacy of agents currently used for the treatment of toxocariasis in
albendazole and mebendazole resistant cases. The total of 58 patients primarily treated with albendazole and/ or mebendazole
were treated with two of the medicines most commonly used for resistant cases of this infection. 26 with visceral larva migrans,
26 with covert toxocariasis and 6 with ocular larva migrans. Diethycarbamazine and thiabendazole were used in their usual
posologic schedules. The total cure rates achieved with diethylcarbamazine and thiabendazole were, respectively: 75% and 70%
in VLM patients, 85% and 80% in covert toxocariasis. We did not achieve any clinical efficacy or blood results negativity in
patients with OLM. Side effects were of minor importance both in patients treated with thiabendazole and diethylcarbamazine.
Biography
Wojciech Ozimek is a MD Paediatrician, Independent lecturer, researcher and media expert in parasitic and vector-borne diseases in Warsaw, Masovian District,
Poland..
